SCHEDULE 13D/A: Dermata Therapeutics CEO Gerald Proehl Increases Stake Through Private Placement, Boosting Beneficial Ownership to 15%

Dermata Therapeutics, Inc.'s CEO, Gerald T. Proehl, and his investment entity, Proehl Investment Ventures LLC, have significantly increased their beneficial ownership in the company to 15.0% and 14.9% respectively, primarily through participation in a recent private placement.

Summary

• Gerald T. Proehl, CEO of Dermata Therapeutics, Inc., and Proehl Investment Ventures LLC (PIV) have filed an Amendment No. 5 to their Schedule 13D, updating their beneficial ownership.
• As of February 13, 2025, Mr. Proehl beneficially owns an aggregate of 803,751 shares of Common Stock, representing 15.0% of the outstanding shares.
• PIV beneficially owns an aggregate of 799,624 shares of Common Stock, representing 14.9% of the outstanding shares.
• These beneficial ownership calculations are based on 5,358,180 shares of Common Stock outstanding as of February 13, 2025.
• On January 21, 2025, Dermata Therapeutics completed a private placement, issuing 1,935,412 shares of Common Stock, 72,468 pre-funded warrants, and 2,007,880 warrants.
• Company insiders, including Mr. Proehl through PIV, participated in this private placement. PIV purchased 787,402 shares of Common Stock and warrants exercisable for 787,402 shares of Common Stock at a purchase price of $1.27 per share and accompanying warrant.
• The warrants acquired by PIV in the private placement are not included in the current beneficial ownership calculation as they are not exercisable within 60 days of the filing date.
• On January 13, 2025, Mr. Proehl was awarded an option exercisable for 45,000 shares of Common Stock in connection with his services as CEO, with an exercise price of $1.38 per share and a vesting schedule over four years.

Sentiment

Score: 7

Explanation: The document indicates strong insider confidence through increased beneficial ownership and participation in a private placement, which are generally positive signals. However, the contingent nature of warrant exercise and the lack of detailed financial performance data limit a higher score.

Positives

• Increased insider ownership by CEO Gerald T. Proehl and his investment entity, Proehl Investment Ventures LLC, signaling confidence in the company's future.
• Participation of company insiders in the private placement at the same terms as other institutional and accredited investors, indicating alignment of interests.
• The private placement successfully raised capital for the company.

Risks

• The exercise of warrants purchased in the private placement is contingent on stockholder approval of the issuance of the underlying shares, introducing a potential delay or uncertainty.
• Warrants are subject to a beneficial ownership limitation (4.99% or, at the election of the holder, 9.99%), which could restrict immediate full exercise.

Future Outlook

The document indicates that warrants purchased in the private placement will be exercisable beginning on the effective date of stockholder approval of the issuance of the underlying shares and will expire five years from that approval date. Additionally, stock options awarded to Mr. Proehl on January 13, 2025, will vest over a four-year period.

Management Comments

• "Mr. Proehl may be deemed to beneficially own an aggregate of 803,751 shares of Common Stock reported herein."
• "Company insiders, including Mr. Proehl (through PIV) participated in the Private Placement."
• "The purchase price per share of Common Stock and accompanying Warrant for PIV was the same as paid by other investors in the Private Placement."

Industry Context

This filing is an ownership disclosure and does not provide specific details on broader industry trends or competitive landscape. However, insider participation in a capital raise is a common event across industries, often signaling management's confidence.

Related Party Transactions

• Company insiders, including Mr. Proehl (through PIV), participated in the private placement, purchasing 787,402 shares of Common Stock and accompanying warrants.
• Mr. Proehl was awarded an option for 45,000 shares of Common Stock in connection with his services as CEO.

Stakeholder Impact

• Shareholders: Increased insider ownership may signal confidence, potentially positively influencing investor sentiment. The private placement dilutes existing shareholders but provides capital to the company.
• Employees: The CEO's stock option award aligns his interests with long-term company performance.

Next Steps

• Stockholder approval is required for the issuance of shares underlying the warrants purchased in the private placement.
• Warrants will become exercisable upon stockholder approval and expire five years thereafter.
• Mr. Proehl's newly awarded stock options will vest over a four-year period, with the first 25% vesting on the 12-month anniversary of the grant date.

Key Dates

Recommendation

Keywords

Dermata Therapeutics, DRMA, Schedule 13D, Beneficial Ownership, Insider Ownership, Private Placement, Gerald T. Proehl, Proehl Investment Ventures LLC, Common Stock, Warrants, Stock Options, SEC Filing, Biotechnology, Pharmaceuticals